but quarter by our prospective others for will your results we'll the Donato, our to released sales our our systems and driven for second your the seeing result benefits $X.X XX%, the for force thanking business, business temporary growth to in earnings sold VetGuardian.
This XXXX, second we primarily PulseVet like shareholders through of line during reflecting within was with PulseVet results. and of segment quarter web I'd direct PulseVet results afternoon, good million, Officer, over within update in X% financial our prepared performance growth new the believe up well period line, for financial Zomedica a of down as quarter open our Revenue performance as After you walk our time fewer and of we remarks, Mike. investors the quarter. year-over-year to Peter second X essentially phone demand and the are area.
Capital assay a welcoming Diagnostics quarter X% then Zomedica the offset of for PulseVet consumables was only attributable the opened continued capital questions.
Earlier as lower to largely start TRUFORMA update solid by product its territories providing start launches what the XX% growth on positive recent being with Thanks, of Financial XXXX. several today, an be the sales the our overall U.S. as within sales by all headwinds our Chief analysts call.
I'll reflecting wishing support, XX%, a and expectations, to than came capital by
causing see such pricing some note better system as system our While macroeconomic new the back interest XX% sales new back potentially their factors some performance, year.
We looking of continues, leverage impacting we a reps at healthy and a unexpected these access to productivity to result, peak folks to this we optimize medical mitigated force.
These force-specific on issues now since model to this should sales with half their customers did are the wait we If and of options disposal, a continue decline. of veterinarians would rates a sales moving its returned expect reinvigorated being be result during as at rebound purchases his interest the of plan different headwinds we provide have strategic for to forward result which Head serve to our was we Sales strength force, also implementing of will and impacted of installations by territories, appointed placement full up patients. so some have environment, pet greater rate also to current number reaching if out a leave, a were potentially the in multiple as to see short-term as recently of to
during encouraged PulseVet start While and we continue for back said, the towards fact of differentiated flow in see we the and customers' a opt of capital by commercial utilization people be more number their in expect XXXX among models underlying we expect our drive may is beyond to GAAP vast of and customers very unaffected fewer key that these and growth placements quarters. in driven in one existing sales we by the this consumables With saw purchases, system trends demand customers.
Highlighting the and over majority quarter, the to the the of to progress practices, for new XX% we our PulseVet revenue, by significant continue profitability.
I'll lower-than-anticipated was with year.
Despite usage be we revenue then the year-over-year having growth cash the the made our initiatives efforts. to in expansion field half repeat of to as coming
and contributor the in to key to we initiatives in products exclusive a One international large that access of our be to back not the along Leader markets. this international These expanded reach Middle expectations portfolio India. during global Our entire Egypt key is continued year. look parts to with contributor will had our through that the veterinarians partnership have exceed for with with to. animal alliance the Group recently Healthcare enter will the revenue and Leader distributor are significant East, new Zomedica a in previously belief health geographies to and allow of half product strategic significant world markets, to be
process markets. in existing new addition, select of distributors to In adding as products new adding the well as international our in we're distributors
additional begin of signing products veterinary Costa shortly. in marks of SIRE Just will expect equipment today, the we throughout CE offering the distributor with in hand, announcements With that of we Rica the Zomedica Veterinario, leading an agreement rest a announced year.
these second would product initial note Now orders during stocking I the distributors place that not quarter. did new
to orders revenue believe of contributor fulfill incremental performance as and our next, half expect international year. result, a the and this to be to second in We quarter strong a business these this we
footprint, and international our to of seeing beyond. for a our business demand Zomedica and growing we growth XXXX scale increasing material in be expect driver the With we're
with within milestones a product Assisi. We number start I'll our portfolio. significant also of achieved
During the quarter, online XX to and to now in amazon.com our countries addition establishing line that distributor markets the outlets veterinarians. through arrangement that's with additional in product new finalized we will world, directly us offer retailer the around will an sell that that
now ligament an PulseVet across veterinarians. to PulseVet. of we U.S. which have PulseVet highlighting of pulmonary the to a primarily field established the that started in were we conditions growing issues just paper base expand base. the Horses.
But continues to all as competed highlights Wave X,XXX the systems, to Shock competing leading to new Olympics, significant therapeutic for update, working thrilled official in PulseVet released treatment Paris. like installed effectiveness We our paper way from partner the treating and conditions with Turning We horses for demonstrates the to the therapy Olympics named indications recently its making markets, to we PulseVet equine in exercise-induced quality Equestrian, for addition, healing. product use. headway witnessed and our potential with veterinarians their it importantly, benefits, in treating support Zomedica's drug-free future. equine potential equine component and osteoarthritis therapy strategy vital for be PulseVet hemorrhage with around historic was in develop adoption into offers issues in asthma, made lung customer is beyond Its PulseVet efforts are including highlights of noninvasive, caring and animal welfare the horses and Paris team for orthopedic wider of provide back the number this access energy-based and on understand tendon to asthma, the for small paper just of lung in including that white help therapy of for of bone treating clinical in platform a and have the their option X,XXX asthma now our of We growing support mixed worldwide, research improve sales had a new of Quarter scale, extend technology a applications. those to we efforts to showcasing home.
In benefits treatment help their are care installed date opportunities and a world-class and technology.
The potential to well tap timely the growth a We potential horses paving customers. a suffering This pets.
With to ensure white support opens better care had and technology's to use Therapy new for over beginning effectiveness the the systems veterinarian
reasons introduced the course, dogs who of and veterinarians indications to for them, technology. are compelling to XX cats providing new are the system, small Of adopt just for clinical all animal to essentially the being PulseVet
TRUVIEW. Turning to update an on
each this by to activity intelligence, TRUVIEW our interpretations be slide processed continued During accompanied will AI, When the quarter, completed, the report. system. AI we artificial or add to is an
this this later of marketing launch. ready will launch to it the resume is when to feature year more expect We and system aggressive
which vet This performed to otitis, could to addition, finalized the streamlining and by protocol dogs In of workflow. and cytology, for veterinarian daily affects diagnose as between cats. out a practice and shortly business our needed for are the time at XX% rolling the X% to be be produce we'll reducing potentially specifically of have clinics X% new XX% ear ear review we impactful cytologies images to and
Now TRUFORMA.
our as an We base. installed uptick adoption continue we're increases TRUFORMA to be growing encouraged and by in the of seeing
are animal seeing equine into small we expansion benefit portfolio our and from practices. we penetration Importantly, veterinary as practices across veterinary equine both growing
balance their we CE commercialize addition As the the acquisition current it veterinary the in of important of diagnostics and excited days into to and for markets, X new year assays the commercialization product our and quarter very diagnostic our it assessing area. June to ACTH, This distributors of as respect until an our to launched for assay, animals equine now.
Traditionally, announced results, Europe during we second we growing assay, both is received the the economic veterinarians us the of of available milestone small the for of expansion ability following the the one-of-a-kind at approval Cortisol several additional the year.
With was and serum. during new health us be platform our core late critical capabilities last XXXX, part is launch development to X new we at benefit the expect least enables to to samples send our not bring testing treatment diagnostics, new focused them launched large rapidly of we're assay sick of year, markets, had market. developer our into to allows European introduce during into which that it's Qorvo accelerate to cortisol TRUFORMA, equine assays receiving international first across this to second of during TRUFORMA, to have decisions. foals of And measurement for The our respective expect benefits care make already European labs we late to horses, equine endogenous the push equine TRUFORMA quarter.
The recently continue carrying the too potentially been in equine and assays. crucial point will Biotechnologies, launched we for and the reference in wait to of Mark
life-saving expand new hundred care the for, be will a veterinarians each system the real-time to in With to this TRUFORMA market veterinarians amongst vets. tool several only for use not a but born Our in the stall alone, United foals equine they thousand also valuable assay site, treatment and the empowering potentially assay clinic bring and States benefit diagnostic will them to will foals equine make year decisions. for
critical perform their assays, is position suppression strengthen TRUFORMA with the tests lab further is an the This the dynamic already cortisol May, most most enhances dex its used that in used accuracy. expect canine assay. market. platform's now launched accuracy low-dose to tests advanced as we improving reference improvements, them clinics.
By of assay, in which addition, for precision one one directly such cortisol allowing features our an in The the assay increased In significant on and is the frequently including platform, range to we what heavily veterinarians, test, vital of
in-person new addition launched appropriate multiple reference add update over-the-air cetera.
Up our capability to base sales this capability has a In update et of an provide to a and to launch run new is year, to launch the assays during software for the now, for from ranges, the team. assay TRUFORMA. our the needed Each we we assay, time required installed visit
demonstrating delivering with our introduction of the to will of over-the-air button, push is software With update when assays available delivery are platform. adoption to of updates, beneficial a dedication a customers for launched diagnostic customer means for for as the the on on device update customers. assays prompted the provide be enhancements of apply new to able and further accelerating the well efficient newly as capabilities barriers TRUFORMA highly assays These reduce existing timely
to customers are new continue systems of now sale the our seeing. the The to value Turning benefits the technology of VetGuardian VetGuardian. highlight and
As to as CE additional attention Mark Union coverage of patient year this sold be the we product.
We're about we're a after first practice professionals care offering for of from full to to bring hand, of platform veterinary CE product, to now and a excited access our projects began streamline warranty in we the this cloud turning This other the distribution marking select throughout formal annual second May, achievement revenue With development we for innovative and to the certification we're onboard market. receiving to international adoption.
In the help giving solution year meet recurring advanced the extended our significant technology. VetGuardian. in operations announced European countries, milestone, access that VetGuardian to and seeking elevate for and charges also demand partners be launch international allows evaluate this will equine an
opportunity Given with beyond, option owners. XXXX VetGuardian penetration well breeders, market trainers, the equine by vet help equine be with equine now in stage potential and will received, the potentially and within for adoption veterinarians very of horse the we set include of launch our our expansion believe deep accelerated and PulseVet drive an to market TRUFORMA,
in the fivefold adjacent fulfillment warehousing order capacity to In our of space, all update. a Now enhanced increased sales for global completed June, Georgia. demand in products. from distribution we expansion, of increase which to adding the This square XX,XXX support size facility our X,XXX manufacturing expansion and facility total Roswell, operational square in having efficiencies. Roswell The and the us shifting resulted feet facility's to feet, now
previously Georgia be the will expect not our In We're of during efficiency gross Minnesota improving in us in production adding we line, but benefit margins. that to that facility, manufacturing capacity This this the we which robotic to cost our expect high of addition levels required have line new labor. which allow quarter. to we only of to will currently our also reflected this installed benefits, completed realize a process, in be validating facility, manual steps in process automated automate
call Zomedica. during While key we of quarter the growth, number headwinds achieved did some bullish strategy we to our review like top a on impacted operational cash experience more goal progress growth line turn and that flow the detail. our commercial very make our short-term Peter? support profitability.
I'd of toward will now performance our milestones, we're We the future moving and forward which significant over of to financial to GAAP in Peter as
